RSP Systems A/S, a Danish medical technology company focused on the development of innovative glucose monitors, today announced its participation in the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). ATTD, one of the world’s leading scientific forums for showcasing the latest breakthroughs in diabetes technology, will be held in Berlin later this week.

Set to make its first conference appearance as an exhibitor at the prestigious New Technologies Fair, RSP Systems will unveil the version of GlucoBeam to be used in the company’s upcoming pivotal trial, a key step towards obtaining regulatory approval in Europe. The device represents the culmination of over 10 years of research and testing to integrate the company’s proprietary critical depth Raman technology into an all-in-one consumer glucose monitor for daily home-use. While the hardware is similar to the future commercial version, the software is still being finalised in preparation for GlucoBeam’s market launch.

"We are extremely excited about the opportunity to introduce RSP Systems to industry specialists, scientists and key opinion leaders at ATTD," said Anders Weber, CSO, who will be giving a talk at the fair. "We are also thrilled to showcase our trial-ready device and look forward to making the premium consumer version of GlucoBeam available to the public in the near future."

About ATTD
ATTD, the 12th International Conference on Advanced Technologies & Treatments for Diabetes, will be held from February 20-23 at CityCube Berlin, Germany. The target audience includes clinicians, scientists, engineers, start-ups and investors who are dedicated to improving the care of people with diabetes at the fastest possible pace.

About RSP Systems
RSP Systems, a Danish medical technology company, is working to produce a non-invasive glucose monitoring device for people with diabetes. The proprietary critical-depth technology that RSP has developed enables, for the first time, non-invasive measurement of glucose in the skin. Having integrated this technology into a consumer device with proven performance in clinic and home settings, RSP plans to begin clinical trials for regulatory approval in Europe. RSP has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 738973.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.